<DOC>
	<DOCNO>NCT01151098</DOCNO>
	<brief_summary>The objective study evaluate long-term safety tolerability 7-day BTDS 28-week open-label extension phase subject chronic nonmalignant pain syndrome whose pain previously control oral opioid combination therapy .</brief_summary>
	<brief_title>Safety Buprenorphine Transdermal Systems Subjects With Chronic Nonmalignant Pain - 28-week Extension Study</brief_title>
	<detailed_description>Upon enter extension phase ( BUP3201S ) , subject receive BTDS 5 , regardless dose level discontinuation completion BUP3201 core study . Subjects allow titrate 48 hour BTDS 10 20 provide stable pain control minimal tolerability problem . Additional medical therapy permit necessary , restriction concomitant analgesic medication . The subject weekly visit 4 consecutive week , every 4 week thereafter , end schedule extension phase .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Include : Subjects either sex age 18 year old . Subjects complete discontinue doubleblind evaluation phase study BUP3201 eligible continue receive openlabel BTDS extension . Include : Subjects currently receive daily morphine oxycodone ( monotherapy ) . Subjects discontinue BUP3201 due adverse event . Subjects schedule surgery disease site ( e.g . major joint replacement surgery ) major surgery would fall within study period . Refer core study additional inclusion/exclusion information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic nonmalignant pain</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Butrans ( BTDS )</keyword>
</DOC>